ALPK1 and retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome: With the discovery of the potent, selective ALPK1 inhibitor DF-003, there is also the potential to further interrogate ALPK1 biology in ROSAH syndrome through ex vivo analyses of patient-derived cells, mouse model experiments, and human clinical trials.